Dulaglutide vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideImmune SupportRecovery & Repair
ARA-290- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- ~5 days
- ~2–4 hours (SC administration)
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 4 mg (fixed dose)
- Frequency
- Once weekly
- Once daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —